Health Trials

Ann Arbor Stage III Follicular Lymphoma

2

Review clinical trials related to Ann Arbor Stage III Follicular Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of WashingtonUpdated: Mar 13, 2026Locations: 1
Eligibility criteria

18 years or older at time of signing informed consent [+22]

History of severe allergic reaction to monoclonal antibody therapy [+11]

Read more
Status: Recruiting

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Chinese PLA General HospitalUpdated: Jul 18, 2024Locations: 1
Eligibility criteria

A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated [+15]

ECOG≤ 2 [+14]

Read more